In this issue of Cancer Cell, Herrero and colleagues identify an anti-tumorigenic small molecule that blocks ERK dimerization, but neither its catalytic activity nor its phosphorylation by MEK. These findings demonstrate that targeting protein dimerization could be a therapeutic avenue for inhibiting kinase signaling pathways associated with lower drug resistance.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Aug 10 2015|
ASJC Scopus subject areas
- Cell Biology
- Cancer Research